ArticlePediatric transplantation2026
Fatal Renal Mucormycosis Following Pediatric Deceased Donor Kidney Transplantation in a High-Risk Recipient: A Case Report.
Article in Pediatric transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucormycosis is a rare but devastating opportunistic fungal infection in immunocompromised hosts with particularly high morbidity and mortality in solid organ transplant recipients. Pediatric cases are exceedingly rare, and outcomes are often fatal. CASE PRESENTATION: We report a case of a 13-year-old girl on chronic peritoneal dialysis who received a deceased donor kidney transplant. She was at immunological risk due to a positive virtual crossmatch. Induction therapy included antithymocyte globulin and methylprednisolone, followed by a maintenance immunosuppressive regimen of prednisone, mycophenolate mofetil, and tacrolimus. Post-transplant, she developed early graft dysfunction, anuria, and hemodynamic instability. A graft biopsy showed acute tubular necrosis and C4d positivity prompting plasma exchange for suspected antibody-mediated rejection. Graft explant on day nine revealed angio-invasive mucormycosis due to Rhizopus arrhizus. The rapid onset suggested the infection may have been acquired from the donor. Despite antifungal therapy, she suffered from recurrent arterial pseudoaneurysms in the surgical bed. She died 91 days post-transplant from a ruptured iliac artery mycotic aneurysm.
conclusionThis case highlights the challenges in diagnosing and managing mucormycosis in pediatric kidney transplant recipients. A high index of suspicion together with early recognition, aggressive surgical management, and appropriate antifungal treatment is essential. Donor derived fungal infections should be considered in cases of early onset disease. Unfortunately, outcomes remain poor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.